Veradigm RxTruePrice Helps Drive Higher Medication Adherence
March 12 2020 - 8:01AM
Business Wire
Allscripts business unit addresses need for
better patient medication adherence through pricing
transparency
Allscripts Healthcare Solutions (NASDAQ: MDRX) and its payer and
life science business unit, Veradigm™, announced its findings on
the impact of Veradigm’s RxTruePrice™, a solution designed to
address patient challenges resulting in them foregoing,
discontinuing or substituting their prescribed medication due to
cost and a lack of prescription drug price transparency.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200312005092/en/
Recent studies have revealed alarming statistics surrounding low
medication adherence. For example, 33% of patients have purposely
missed filling a prescription due to its prohibitive cost.1 And
nearly 6% of patients have skipped taking their medications three
times or more.1
Patient outcomes may improve if it were easier to ensure
patients stay on their prescribed medication regimen by knowing the
cost before they leave their doctor’s office. Higher out-of-pocket
cost of prescription medications have been shown to correlate with
increased prescribed prescription abandonment. With patients
incurring a higher share of their healthcare costs, Veradigm’s
RxTruePrice can help the 42% of Americans, who have reported they
are struggling to pay for their necessary medication, gain a
clearer view into pricing. 1
A recent Veradigm fielded study found that six out of ten
RxTruePrice users have observed an overall improvement in patient
prescription medication adherence since launching the solution.2
Users also felt that the availability of pricing data within their
regular workflow held the potential to help them improve medication
adherence as compared to alternate solutions, such as sponsored
patient support programs and patient reminders.2
Used by tens of thousands of providers for tens of millions of
price transparency transactions, Veradigm RxTruePrice provides
users access to discounted health plan or pharmacy-benefit pricing,
cash pricing, therapeutic alternatives and competitive prices at
local and mail-order pharmacies. Further, all information is
specific to each individual patient and is accessible in the
provider’s e-prescribing workflow.
“Everyone knows healthcare costs are rising and people’s incomes
can’t always keep up,” says RxTruePrice client Dr. Darla Kincaid of
MD Pediatric Associates, in Coppell, TX. “Having that patient’s
drug pricing information right there in the EHR, it makes for a
phenomenal tool. It has helped us improve medication adherence as a
practice, but just as importantly, it helps us better engage our
patients. By demonstrating we share their concerns on cost of care,
it makes us a team, and that is the goal.”
“Veradigm RxTruePrice is positioned to help bridge the gaps
created by pharmaceutical companies’ pricing structures and
positive patient outcomes,” said Veradigm CEO Tom Langan,
“medication adherence is not a new problem, but now, it is a
problem with a solution.”
Learn more about the impact of Veradigm RxTruePrice solution
here.
1. Hamm, N. Managed Healthcare Executive. How High Drug Prices
Affect Patients. May 2019. Available at
https://www.managedhealthcareexecutive.com/drug-price/how-high-drug-prices-affect-patients
2. Results of Veradigm ePrescribe user survey conducted
September 2019. Data on File.
About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information
technology solutions that advance clinical, financial and
operational results. Our innovative solutions connect people,
places and data across an Open, Connected Community of Health™.
Connectivity empowers caregivers and consumers to make better
decisions, delivering better care for healthier populations. To
learn more, visit www.allscripts.com, Twitter,
YouTube and It Takes A Community: The Allscripts
Blog.
© 2020 Allscripts Healthcare, LLC and/or its affiliates. All
Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are
trademarks of Allscripts Healthcare, LLC and/or its affiliates. All
other products are trademarks of their respective holders, all
rights reserved. Reference to these products is not intended to
imply affiliation with or sponsorship of Allscripts Healthcare, LLC
and/or its affiliates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200312005092/en/
For more information contact: Investors: Stephen Shulstein 312-386-6735
Stephen.Shulstein@allscripts.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Jul 2023 to Jul 2024